title: [Randomized systemic chemotherapy using two or three drug combination for small cell lung cancer (SCLC)].
abstract: Randomized trials were sequentially performed in SCLC patients using a two-drug combination (ACNU . VCR, ADM . VCR) and a three-drug combination (ACNU . CPA . VCR, ACNU . ADM . VCR). The response rate for the two-drug regimen was 36.4% (8/22 cases) and that for the three-drug combination was 60.0% (15/25 cases). The median survival time of the two groups was 7 and 9 months, respectively. The group with PS. 0-1 showed a better prognosis than that with PS. 2-3 (p = 0.03). No fatal side effects were experienced in this protocol. These data suggest that the three-drug combination (ACNU . VCR . CPA) represents an active regimen for SCLC.
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D015376:Nimustine; D009607:Nitrosourea Compounds / Q000008:administration & dosage; D011897:Random Allocation; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D009607:Nitrosourea Compounds; D015376:Nimustine; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide